ARMP Profile
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology firm, is dedicated to pioneering targeted bacteriophage therapeutics to combat antibiotic-resistant infections on a global scale. The company leverages its proprietary bacteriophage-based technology to develop novel treatments for severe bacterial infections that are increasingly resistant to conventional antibiotics. Armata’s approach focuses on utilizing bacteriophagesâ€viruses that infect and kill bacteriaâ€as a precise and effective solution to address these challenging infections.
The company’s primary product candidates include AP-SA02, which targets Staphylococcus aureus bacteremia, a serious bloodstream infection; AP-PA02, designed for Pseudomonas aeruginosa, a common and often resistant pathogen; and AP-PA03, aimed at treating pneumonia caused by resistant bacterial strains. These therapeutic candidates represent Armata’s commitment to advancing innovative treatments that address critical gaps in the current antimicrobial arsenal.
In addition to its internal development efforts, Armata Pharmaceuticals has formed a strategic partnership with Merck & Co. This collaboration focuses on developing synthetic bacteriophage candidates targeting undisclosed infectious disease agents, further expanding the potential applications of its technology. The partnership underscores Armata’s strategic approach to leveraging external expertise and resources to accelerate the development of its advanced therapeutics.
Headquartered in Marina del Rey, California, Armata Pharmaceuticals operates at the forefront of biotechnology innovation. The company’s focus on bacteriophage-based therapies positions it as a key player in the fight against antibiotic-resistant infections, an area of growing concern in global healthcare. Through its advanced research and strategic partnerships, Armata is dedicated to bringing new, effective treatments to market and addressing the pressing need for solutions in the fight against resistant bacterial infections.
|
